Description: Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Home Page: www.sumitomo-pharma.com
6-8, Doshomachi 2-chome
Osaka,
541-0045
Japan
Phone:
81 6 6203 5321
Officers
| Name | Title |
|---|---|
| Mr. Toru Kimura Ph.D. | Representative Director, President & CEO |
| Motoyuki Sakai | Representative Director and Executive VP of Corporate Planning, Corp. Governance, HR & Accounting |
| Mr. Hiroyuki Baba | Mngg Exec. Officer of Global Data Design, Lgl Affairs. IP, IT Mgt, & Frontier Bus. Off. |
| Mr. Naoki Noguchi | Executive Officer of Corporate Governance & Communications, VP and Head of Corporate Communications |
| Mr. Yoshiharu Ikeda Ph.D. | Managing Executive Officer of Drug Research Division, Head of Japan Business Unit & Director |
| Mr. Koichi Kozuki | E.O. of R. Aff., Med. Sci., C.R.C. & Q.A., Sr. VP, Hd of C.R.C. & Q.A. Div and Dp. Hd of Japan Bus. |
| Dr. Shigeyuki Nishinaka Ph.D. | Managing Executive Office, VP and Head of Business Development & Management |
| Mr. Isao Shimizu | Executive Officer, Senior VP, Head of Drug Research Division & Senior Executive Research Director |
| Mr. Kenji Ueno | Executive Officer, Senior VP and Head of Technology Research & Development Division |
| Mr. Hideyuki Harada | Managing Exe. Officer of Tech. R&D Div., Manufacturing Div. and Dep. Head of Japan Bus. Unit |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 21.1864 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1723 |
| Price-to-Sales TTM: | 0.0048 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 4980 |